Welcome
Support Centre
29 August 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A randomised trial of chemotherapy with or without granulocyte colony-stimulating factor (G-CSF) in operable osteosarcoma
ISRCTN ISRCTN86294690
ClinicalTrials.gov identifier
Public title A randomised trial of chemotherapy with or without granulocyte colony-stimulating factor (G-CSF) in operable osteosarcoma
Scientific title
Acronym N/A
Serial number at source BO06
Study hypothesis To compare two regimens of chemotherapy using Doxorubicin and Cisplatin in operable osteosarcoma: one involving chemotherapy at three weekly intervals with surgery after two courses, the other, chemotherapy at two weekly intervals plus G-CSF with surgery after three courses.
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Osteosarcoma
Participants - inclusion criteria 1. Untreated non-metastatic disease
2. Age less than or equal to 40 years
3. Neutrophils ≥1.5 times 10^9/l and platelets ≥100 times 10^9/l
4. Glomerular Filtration Rate (GFR) ≥60 ml/min/1.73 m^2
5. Serum bilirubin ≤ micromoles/L
6. Normal cardiac function
7. Informed consent
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/07/1993
Anticipated end date 30/09/2002
Status of trial Completed
Patient information material
Target number of participants 500
Interventions Two regimens of chemotherapy:
1. The first is Doxorubicin and Cisplatin at three weekly intervals with surgery after two courses/chemotherapy.
2. The second is Doxorubicin and Cisplatin at two weekly intervals plus G-CSF with surgery after three courses.
Primary outcome measure(s) 1. Survival time
2. Response rate
3. Morbidity
4. Response duration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Medical Research Council
Trial website
Publications Results on http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=17227995
Contact name Dr  Barbara  Uscinska
  Address MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Email unknown@contact.com
Sponsor Medical Research Council (MRC) (UK)
  Address 20 Park Crescent
  City/town London
  Zip/Postcode W1B 1AL
  Country United Kingdom
  Tel +44 (0)20 7636 5422
  Fax +44 (0)20 7436 6179
  Email clinical.trial@headoffice.mrc.ac.uk
  Sponsor website: http://www.mrc.ac.uk
Date applied 28/02/2001
Last edited 06/03/2007
Date ISRCTN assigned 28/02/2001
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central